4 New Stocks I will Probably Insert to My Portfolio in 2022

Table of Contents

New 12 months, new you, new portfolio additions?

As we get ready to transform the page on 2021, I are not able to enable but take note how we’ve witnessed a fairly substantial market place bifurcation in stocks more than the previous few of quarters. Even while the wide market place indexes have strike all-time highs, quite a few development stocks and small-cap plays have entered bear market place territory. In other words, a great deal of opportunity abounds, even with the important indexes in the vicinity of a record large.

A variety of shares on my view record that I’ve not owned ahead of are getting awfully close to amounts exactly where I may well not be in a position to resist buying. Below are four shares that I feel are probably to discover their way into my portfolio in 2022.

Impression supply: Getty Images.


A 12 months ago, I was completely towards electric motor vehicle (EV) manufacturer Nio (NYSE:NIO). The concept that an unproven automaker kicking out about 20,000 EVs annually could command a $90 billion sector cap was so ludicrous that I under no circumstances considered I’d think about purchasing it. And nonetheless, listed here we are.

Approximately a single year later I can say that I am thoroughly impressed with the way Nio’s administration has ramped up production in the wake of pandemic provide issues and bigger inflation. I imagine the company’s innovation will generate industry share gains in China for several years to appear.

In terms of output, Nio sent near to 10,900 EVs in November, which puts it on an extrapolated run-charge tempo of 130,000 EVs a 12 months. By the finish of next year, the enterprise anticipates an annual operate price of 600,000 EVs. With Nio introducing 3 new EVs upcoming calendar year, as effectively as organically escalating sales for its current lineup of SUVs and its crossover EV, it could place Tesla Motors‘ ramp-up to disgrace.

I am specifically impressed with Nio’s battery-as-a-company (BaaS) method. With BaaS, consumers receive a discount on the preliminary purchase cost of their vehicles, and are ready to cost, swap, and improve their batteries in excess of time. The benefit for Nio is enhanced purchaser loyalty to the manufacturer and higher-margin cost revenue for years right after buy.

If you can find a pure-participate in EV maker that has my full and undivided attention, it really is Nio.

A clear jar packed with dried cannabis buds that's set atop a neatly fanned pile of twenty dollar bills.

Graphic source: Getty Visuals.

Cresco Labs

In a marketplace in which most growth shares are even now valued at substantive premiums, some of the best offers can be discovered in the hashish space. Marijuana stock Cresco Labs (OTC:CRLBF) is 1 these kinds of title that I consider I will pull the cause on in 2022.

To handle the elephant in the room anytime pot stocks are discussed, federal legalization would be great, but it is just not required for weed stocks to prosper. With 36 states possessing legalized hashish in some ability, and the federal govt permitting person states to control their industries, there is a sizable path for marijuana stocks like Cresco Labs to realize success.

Like practically all multi-condition operators, Cresco Labs is performing on constructing up its retail existence — not too long ago opening its 45th spot nationwide. However, it truly is primarily centered on pushing into huge-dollar limited-license marketplaces, this kind of as Illinois and Ohio. Marketplaces exactly where regulators purposely limit the amount of retail licenses issued guarantee that Cresco has a good shot at developing up its model(s) and garnering a loyal following.

But the finest detail about Cresco Labs is its field-main wholesale section. Wall Street generally writes off wholesale cannabis for its bad margins. But when we’re conversing about a company like Cresco, which retains a cannabis distribution license in California, the biggest pot sector in the entire world, quantity makes up for any margin considerations.

A physician administering a vaccine into the upper-right arm of a patient.

Picture supply: Getty Photos.


Yet another high-development corporation I am eyeing that I hope to add to my portfolio at some place in 2022 is biotech inventory Novavax (NASDAQ:NVAX).

Considerably very similar to Nio, I was of the belief that chasing COVID-19 vaccine stocks at the starting of 2021 would be a inadequate shift. In numerous situations, I felt COVID-19 shares were being grossly overpriced, specifically not recognizing more than enough about the illness and its variants. Immediately after another calendar year of digesting knowledge, I am prepared to crown Novavax as the most beautiful COVID-19 perform.

As some of you might already know, Novavax unquestionably dazzled with its clinical demo info for NVX-CoV2373. A March-produced U.K. analyze and a June-announced U.S./Mexico trial demonstrated respective vaccine efficacy (VE) of 89.7% and 90.4%. This will make Novavax one particular of 3 COVID-19 vaccine producers to strike a 90% VE level, which really should enable it to develop into a important player globally.

The only motive Novavax’s share price tag failed to blast off into the heavens has been its delays in submitting for unexpected emergency-use authorization in important marketplaces and creation delays. Luckily, these problems are remaining pushed into the rearview mirror, and nations are beginning to give Novavax a inexperienced light-weight.

What’s additional, variants of the sickness make it most likely that COVID-19 results in being endemic. This indicates Novavax could be a winner from preliminary inoculations, booster pictures, and possibly even combination vaccines with influenza, which the enterprise is establishing and screening.

A hacker wearing black gloves who's typing on a keyboard in a dark room.

Image resource: Getty Images.

Ping Id Holdings

The fourth and final new stock that I’ll probable increase to my portfolio in 2022 is cybersecurity perform Ping Identity (NYSE:PING).

There are no scarcity of double-digit advancement developments investors can set their money to work in ideal now. But I consider the safest double-digit progress craze throughout the decade is heading to be cybersecurity. It really is progressed into a fundamental require assistance, and a lot more organizations than at any time are transferring their info, and that of their customers, into the cloud. Which is a recipe for results for third-party alternative companies like Ping.

Like most substantial-doing protection offerings, Ping’s cloud-dependent platform is leaning on artificial intelligence. It is really correctly starting to be smarter at recognizing and responding to threats above time. Wherever Ping Identification can provide the biggest value is currently being layered atop on-premises remedies. Ping’s infrastructure fills the gaps the place on-premises stability fails by supplying ongoing consumer monitoring, verification, and authorization.

Ping Identity is also producing headway in its thrust to change consumers away from term-dependent subscriptions to software-as-a-services (SaaS) subscriptions. The latter should really result in greater very long-phrase margins and improved retention costs. Preserve in thoughts that membership gross margin is now hovering all over a juicy 85%.

Whilst most cybersecurity shares are nonetheless valued at nosebleed sales multiples, Ping is successful and can be scooped up for about 6 situations Wall Street’s believed income for 2022. Which is a heck of a cut price for what ought to be a long-time period cybersecurity winner.

This posting represents the impression of the writer, who may possibly disagree with the “official” recommendation situation of a Motley Fool high quality advisory provider. We’re motley! Questioning an investing thesis — even just one of our have — allows us all imagine critically about investing and make conclusions that help us turn into smarter, happier, and richer.